The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...
Because of the near-simultaneous approval of new metastatic RCC therapies that act on VEGF and the HIF transcription cascade, Trx inhibitors such as MGd should be explored as potential candidates ...
Dr. Heather Wakelee examines the increasingly routine use of adjuvant therapy for patients with early stage non-small-cell lung cancer. Experts And Viewpoints, July 17, 2008 Oral VEGF Therapies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback